We are live on ! Find out more
BBLGW

Bone Biologics Corp Warrants
BBLGW

5 hedge funds and large institutions have $62K invested in Bone Biologics Corp Warrants in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 55 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

54% less capital invested

Capital invested by funds: $134K → $62K (-$72K)

Holders
5
Holders Change
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
1
Reduced
1
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

Rank Fund Capital Flow
1
CS
Clear Street
New York
+$939

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$1.64K
Name Holding Trade Value Shares
Change
Change in
Stake
WAM
1
Warberg Asset Management
Illinois
$21K
EAM
2
Empery Asset Management
New York
$20K
SM
3
Sabby Management
Florida
$16K
CS
4
Clear Street
New York
$4K +$939 +126 +19%
UBS Group
5
UBS Group
Switzerland
$1K -$1.64K -220 -61%

BBLGW Hedge Fund Activity: Q2 2022 in Review

5 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q2 2022, worth a combined $62K — down 54% from $134K a quarter earlier.

Fund positioning in BBLGW was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Clear Street, adding an estimated $939. The largest seller was UBS Group, cutting an estimated $1.64K.

  • 5 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $62K of Bone Biologics Corp Warrants stock for Q2 2022, down 54% quarter-over-quarter.
  • 0 funds opened new Bone Biologics Corp Warrants positions in Q2 2022 and 0 closed out.
  • The largest Bone Biologics Corp Warrants buyer in Q2 2022 was Clear Street, an estimated $939 added.
  • The largest Bone Biologics Corp Warrants seller in Q2 2022 was UBS Group, an estimated $1.64K sold.

Based on aggregated 13F filings for Q2 2022.